Researchers have announced that the FDA has approved AUVELITY, a new medication designed to treat agitation associated with dementia due to Alzheimer’s disease. This first-in-class treatment combines dextromethorphan and bupropion and aims to alleviate emotional distress and aggressive behaviors often experienced by individuals with Alzheimer’s. Agitation affects up to 76% of those with the disease, making this approval significant for improving quality of life for both patients and caregivers.

For people concerned about aging well, AUVELITY could offer a new option to manage agitation, which is linked to faster cognitive decline and increased caregiver stress. This medication may help reduce disruptive behaviors and emotional distress, potentially allowing individuals with Alzheimer’s to maintain a better quality of life. By addressing these symptoms, it may also lessen the burden on caregivers, who often face increased challenges when caring for agitated loved ones.

The approval of AUVELITY comes after its initial use for treating major depressive disorder. While this approval is a positive step, it’s important to note that AUVELITY is still relatively new, and more research is needed to fully understand its long-term effects and safety specifically for agitation in dementia. As with any medication, individuals should consult their healthcare providers to discuss whether this treatment is appropriate for their situation.

If you or a loved one is dealing with agitation related to Alzheimer’s, it’s worth discussing AUVELITY with a healthcare provider to see if it could be a suitable option. As always, ensure any treatment plan is tailored to individual needs and health conditions.

Source: globenewswire.com